ACTONEL ONCE A WEEK

Main information

  • Trade name:
  • ACTONEL ONCE A WEEK
  • Dosage:
  • 35 Milligram
  • Pharmaceutical form:
  • Film Coated Tablet
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • ACTONEL ONCE A WEEK
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PPA1562/015/001
  • Authorization date:
  • 09-10-2009
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

ActonelOnceaWeek35mgfilm-coatedtablets.

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachfilm-coatedtabletcontains35mgrisedronatesodium(equivalentto32.5mgrisedronicacid).

Excipients:Eachfilm-coatedtabletcontainslactose.

Forafulllistofexcipients,seesection6.1.

3PHARMACEUTICALFORM

Film-coatedtablet

ProductimportedfromtheUKandItaly

Ovallight-orangefilm-coatedtabletwith‘RSN’ononesideand‘35mg’ontheother.

4CLINICALPARTICULARS

4.1TherapeuticIndications

Treatmentofpostmenopausalosteoporosis,toreducetheriskofvertebralfractures.Treatmentofestablished

postmenopausalosteoporosis,toreducetheriskofhipfractures(seesection5.1).

Treatmentofosteoporosisinmenathighriskoffractures(seesection5.1).

4.2Posologyandmethodofadministration

Therecommendeddoseinadultsisone35mgtabletorallyonceaweek.Thetabletshouldbetakenonthesameday

eachweek.Theabsorptionofrisedronatesodiumisaffectedbyfood,thustoensureadequateabsorptionpatients

shouldtakeActonelOnceaWeek35mg:

Beforebreakfast:Atleast30minutesbeforethefirstfood,othermedicinalproductordrink(otherthanplain

water)oftheday.

Patientsshouldbeinstructedthatifadoseismissed,oneActonelOnceaWeek35mgtabletshouldbetakenontheday

thatthetabletisremembered.Patientsshouldthenreturntotakingonetabletonceaweekonthedaythetabletis

normallytaken.Twotabletsshouldnotbetakenonthesameday.

Thetabletmustbeswallowedwholeandnotsuckedorchewed.ToaiddeliveryofthetablettothestomachActonel

OnceaWeek35mgistobetakenwhileinanuprightpositionwithaglassofplainwater(120ml).Patientsshould

notliedownfor30minutesaftertakingthetablet(seesection4.4).

SupplementalcalciumandvitaminDshouldbeconsideredifthedietaryintakeisinadequate.

Theoptimaldurationofbisphosphonatetreatmentforosteoporosishasnotbeenestablished.Theneedforcontinued

treatmentshouldbere-evaluatedperiodicallybasedonthebenefitsandpotentialrisksofrisedronateonanindividual

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/05/2012 CRN 2115488 page number: 1

Elderly:Nodosageadjustmentisnecessarysincebioavailability,distributionandeliminationweresimilarinelderly

(>60yearsofage)comparedtoyoungersubjects.

Thishasalsobeenshownintheveryelderly,75yearsoldandabovepostmenopausalpopulation.

RenalImpairment:Nodosageadjustmentisrequiredforthosepatientswithmildtomoderaterenalimpairment.The

useofrisedronatesodiumiscontraindicatedinpatientswithsevererenalimpairment(creatinineclearancelowerthan

30ml/min)(seesections4.3and5.2).

Paediatricpopulation:Risedronatesodiumisnotrecommendedforuseinchildrenbelowage18duetoinsufficient

dataonsafetyandefficacy(alsoseesection5.1).

4.3Contraindications

Knownhypersensitivitytorisedronatesodiumortoanyoftheexcipients.

Hypocalcaemia(seesection4.4).

Pregnancyandlactation.

Severerenalimpairment(creatinineclearance<30ml/min).

4.4Specialwarningsandprecautionsforuse

Foods,drinks(otherthanplainwater)andmedicinalproductscontainingpolyvalentcations(suchascalcium,

magnesium,ironandaluminium)interferewiththeabsorptionofbisphosphonatesandshouldnotbetakenatthesame

timeasActonelOnceaWeek35mg(seesection4.5).Inordertoachievetheintendedefficacy,strictadherenceto

dosingrecommendationsisnecessary(seesection4.2).

Efficacyofbisphosphonatesinthetreatmentofosteoporosisisrelatedtothepresenceoflowbonemineraldensity

and/orprevalentfracture.

Highageorclinicalriskfactorsforfracturealonearenotsufficientreasonstoinitiatetreatmentofosteoporosiswitha

bisphosphonate.

Theevidencetosupportefficacyofbisphosphonatesincludingrisedronateintheveryelderly(>80years)islimited

(seesection5.1).

Bisphosphonateshavebeenassociatedwithoesophagitis,gastritis,oesophagealulcerationsandgastroduodenal

ulcerations.Thus,cautionshouldbeused:

Inpatientswhohaveahistoryofoesophagealdisorderswhichdelayoesophagealtransitoremptying

e.g.strictureorachalasia

Inpatientswhoareunabletostayintheuprightpositionforatleast30minutesaftertakingthetablet.

Ifrisedronateisgiventopatientswithactiveorrecentoesophagealoruppergastrointestinalproblems.

Prescribersshouldemphasisetopatientstheimportanceofpayingattentiontothedosinginstructionsandbealertto

anysignsandsymptomsofpossibleoesophagealreaction.Thepatientsshouldbeinstructedtoseektimelymedical

attentioniftheydevelopsymptomsofoesophagealirritationsuchasdysphagia,painonswallowing,retrosternalpain

ornew/worsenedheartburn.

HypocalcaemiashouldbetreatedbeforestartingActonelOnceaWeek35mgtherapy.Otherdisturbancesofboneand

mineralmetabolism(i.e.parathyroiddysfunction,hypovitaminosisD)shouldbetreatedatthetimeofstartingActonel

OnceaWeek35mgtherapy.

Osteonecrosisofthejaw,generallyassociatedwithtoothextractionand/orlocalinfection(includingosteomyelitis)has

beenreportedinpatientswithcancerreceivingtreatmentregimensincludingprimarilyintravenouslyadministered

bisphophonates.Manyofthesepatientswerealsoreceivingchemotherapyandcorticosteroids.Osteonecrosisofthejaw

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/05/2012 CRN 2115488 page number: 2

Adentalexaminationwithappropriatepreventivedentistryshouldbeconsideredpriortotreatmentwith

bisphosphonatesinpatientswithconcomitantriskfactors(e.g.cancer,chemotherapy,radiotherapy,corticosteroids,

poororalhygiene).

Whileontreatment,thesepatientsshouldavoidinvasivedentalproceduresifpossible.Forpatientswhodevelop

osteonecrosisofthejawwhileonbisphosphonatetherapy,dentalsurgerymayexacerbatethecondition.Forpatients

requiringdentalprocedures,therearenodataavailabletosuggestwhetherdiscontinuationofbisphosphonatetreatment

reducestheriskofosteonecrosisofthejaw.

Clinicaljudgmentofthetreatingphysicianshouldguidethemanagementplanofeachpatientbasedonindividual

benefit/riskassessment.

Atypicalfracturesofthefemur

Atypicalsubtrochantericanddiaphysealfemoralfractureshavebeenreportedwithbisphosphonatetherapy,primarily

inpatientsreceivinglong-termtreatmentforosteoporosis.Thesetransverseorshortobliquefracturescanoccur

anywherealongthefemurfromjustbelowthelessertrochantertojustabovethesupracondylarflare.Thesefractures

occurafterminimalornotraumaandsomepatientsexperiencethighorgroinpain,oftenassociatedwithimaging

featuresofstressfractures,weekstomonthsbeforepresentingwithacompletedfemoralfracture.Fracturesareoften

bilateral;therefore

thecontralateralfemurshouldbeexaminedinbisphosphonate-treatedpatientswhohavesustainedafemoralshaft

fracture.Poorhealingofthesefractureshasalsobeenreported.Discontinuationofbisphosphonatetherapyinpatients

suspectedtohaveanatypicalfemurfractureshouldbeconsideredpendingevaluationofthepatient,basedonan

individualbenefitriskassessment.

Duringbisphosphonatetreatmentpatientsshouldbeadvisedtoreportanythigh,hiporgroinpainandanypatient

presentingwithsuchsymptomsshouldbeevaluatedforanincompletefemurfracture.

Thismedicinecontainslactose.Patientswithrarehereditaryproblemsofgalactoseintolerance,theLapplactase

deficiencyorglucose-galactosemalabsorptionshouldnottakethismedicine.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

Noformalinteractionstudieshavebeenperformed,howevernoclinicallyrelevantinteractionswithothermedicinal

productswerefoundduringclinicaltrials.

IntherisedronatesodiumPhaseIIIosteoporosisstudieswithdailydosing,acetylsalicylicacidorNSAIDusewas

reportedby33%and45%ofpatientsrespectively.InthePhaseIIIonceaweekstudyinpostmenopausalwomen,

acetylsalicylicacidorNSAIDusewasreportedby57%and40%ofpatientsrespectively.Amongregularacetyl

salicylicacidorNSAIDusers(3ormoredaysperweek)theincidenceofuppergastrointestinaladverseeventsin

risedronatesodiumtreatedpatientswassimilartothatincontrolpatients.

Ifconsideredappropriaterisedronatesodiummaybeusedconcomitantlywithoestrogensupplementation(forwomen

only).

Concomitantingestionofmedicationscontainingpolyvalentcations(e.g.calcium,magnesium,ironandaluminium)

willinterferewiththeabsorptionofrisedronatesodium(seesection4.4).

Risedronatesodiumisnotsystemicallymetabolised,doesnotinducecytochromeP450enzymes,andhaslowprotein

binding.

4.6Fertility,pregnancyandlactation

Therearenoadequatedatafromtheuseofrisedronatesodiuminpregnantwomen.Studiesinanimalshaveshown

reproductivetoxicity(seesection5.3).Thepotentialriskforhumansisunknown.Studiesinanimalindicatethata

smallamountofrisedronatesodiumpassintobreastmilk.

Risedronatesodiummustnotbeusedduringpregnancyorbybreast-feedingwomen.

4.7Effectsonabilitytodriveandusemachines

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/05/2012 CRN 2115488 page number: 3

4.8Undesirableeffects

RisedronatesodiumhasbeenstudiedinphaseIIIclinicaltrialsinvolvingmorethan15,000patients.Themajorityof

undesirableeffectsobservedinclinicaltrialsweremildtomoderateinseverityandusuallydidnotrequirecessationof

therapy.

AdverseexperiencesreportedinphaseIIIclinicaltrialsinpostmenopausalwomenwithosteoporosistreatedforupto

36monthswithrisedronatesodium5mg/day(n=5020)orplacebo(n=5048)andconsideredpossiblyorprobablyrelated

torisedronatesodiumarelistedbelowusingthefollowingconvention(incidencesversusplaceboareshownin

brackets):

verycommon(1/10);common(1/100;<1/10);uncommon(1/1,000;<1/100);rare(1/10,000;<1/1,000);very

rare(<1/10,000).

Nervoussystemdisorders:

Common:headache(1.8%vs.1.4%)

Eyedisorders:

Uncommon:iritis*

Gastrointestinaldisorders:

Common:constipation(5.0%vs.4.8%),dyspepsia(4.5%vs.4.1%),nausea(4.3%vs.4.0%),abdominalpain(3.5%vs.

3.3%),diarrhoea(3.0%vs.2.7%)

Uncommon:gastritis(0.9%vs.0.7%),oesophagitis(0.9%vs.0.9%),dysphagia(0.4%vs.0.2%),duodenitis(0.2%

vs.0.1%),oesophagealulcer(0.2%vs.0.2%)

Rare:glossitis(<0.1%vs.0.1%),oesophagealstricture(<0.1%vs.0.0%),

Musculoskeletalandconnectivetissuesdisorders:

Common:musculoskeletalpain(2.1%vs.1.9%)

Investigations:

Rare:abnormalliverfunctiontests*

*NorelevantincidencesfromPhaseIIIosteoporosisstudies;frequencybasedonadverseevent/laboratory/rechallenge

findingsinearlierclinicaltrials.

Inaone-year,double-blind,multicentrestudycomparingrisedronatesodium5mgdaily(n=480)andrisedronate

sodium35mgweekly(n=485)inpostmenopausalwomenwithosteoporosis,theoverallsafetyandtolerabilityprofiles

weresimilar.Thefollowingadditionaladverseexperiencesconsideredpossiblyorprobablydrugrelatedby

investigatorshavebeenreported(incidencegreaterinrisedronate35mgthaninrisedronatesodium5mggroup):

gastrointestinaldisorder(1.6%vs.1.0%)andpain(1.2%vs.0.8%).

Ina2-yearstudyinmenwithosteoporosis,theoverallsafetyandtolerabilityweresimilarbetweenthetreatmentand

theplacebogroups.Adverseexperienceswereconsistentwiththosepreviouslyobservedinwomen.

Laboratoryfindings:Early,transient,asymptomaticandmilddecreasesinserumcalciumandphosphatelevelshave

beenobservedinsomepatients.

Thefollowingadditionaladversereactionshavebeenreportedduringpost-marketinguse(frequencyunknown):

Eyedisorders:

iritis,uveitis

Muskuloskeletalandconnectivetissuesdisorders:

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/05/2012 CRN 2115488 page number: 4

Skinandsubcutaneoustissuedisorders:

hypersensitivityandskinreactions,includingangioedema,generalisedrash,urticariaandbullousskinreactions,some

severeincludingisolatedreportsofStevensJohnsonsyndromeandtoxicepidermalnecrolysisandleukocytoclastic

vasculitis.

hairloss

Immunesystemdisorders:

anaphylacticreaction

Hepatobiliarydisorders:

serioushepaticdisorders.Inmostofthereportedcasesthepatientswerealsotreatedwithotherproductsknownto

causehepaticdisorders.

Duringpost-marketingexperiencethefollowingreactionshavebeenreported(frequencyrare):

Atypicalsubtrochantericanddiaphysealfemoralfractures(bisphosphonateclassadversereaction).

4.9Overdose

Nospecificinformationisavailableonthetreatmentofoverdosewithrisedronatesodium.

Decreasesinserumcalciumfollowingsubstantialoverdosemaybeexpected.Signsandsymptomsofhypocalcaemia

mayalsooccurinsomeofthesepatients.

Milkorantacidscontainingmagnesium,calciumoraluminiumshouldbegiventobindrisedronateandreduce

absorptionofrisedronatesodium.Incasesofsubstantialoverdose,gastriclavagemaybeconsideredtoremove

unabsorbedrisedronatesodium.

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

Pharmaco-therapeuticgroup:Bisphosphonates

ATCCode:M05BA07.

Risedronatesodiumisapyridinylbisphosphonatethatbindstobonehydroxyapatiteandinhibitsosteoclast-mediated

boneresorption.Theboneturnoverisreducedwhiletheosteoblastactivityandbonemineralisationispreserved.In

preclinicalstudiesrisedronatesodiumdemonstratedpotentanti-osteoclastandantiresorptiveactivity,anddose

dependentlyincreasedbonemassandbiomechanicalskeletalstrength.Theactivityofrisedronatesodiumwas

confirmedbymeasuringbiochemicalmarkersforboneturnoverduringpharmacodynamicandclinicalstudies.In

studiesofpost-menopausalwomen,decreasesinbiochemicalmarkersofboneturnoverwereobservedwithin1month

andreachedamaximumin3-6months.DecreasesinbiochemicalmarkersofboneturnoverweresimilarwithActonel

OnceaWeek35mgandActonel5mgdailyat12months.

Inastudyinmenwithosteoporosis,decreasesinbiochemicalmarkersofboneturnoverwereobservedattheearliest

timepointof3monthsandcontinuedtobeobservedat24months.

TreatmentofPostmenopausalOsteoporosis:

Anumberofriskfactorsareassociatedwithpostmenopausalosteoporosisincludinglowbonemass,lowbonemineral

density,earlymenopause,ahistoryofsmokingandafamilyhistoryofosteoporosis.Theclinicalconsequenceof

osteoporosisisfractures.Theriskoffracturesisincreasedwiththenumberofriskfactors.

BasedoneffectsonmeanchangeinlumbarspineBMD,ActonelOnceaWeek35mg(n=485)wasshowntobe

equivalenttoActonel5mgdaily(n=480)inaone-year,double-blind,multicentrestudyofpostmenopausalwomen

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/05/2012 CRN 2115488 page number: 5

Theclinicalprogrammeforrisedronatesodiumadministeredoncedailystudiedtheeffectofrisedronatesodiumonthe

riskofhipandvertebralfracturesandcontainedearlyandlatepostmenopausalwomenwithandwithoutfracture.Daily

dosesof2.5mgand5mgwerestudiedandallgroups,includingthecontrolgroups,receivedcalciumandvitaminD(if

baselinelevelswerelow).Theabsoluteandrelativeriskofnewvertebralandhipfractureswereestimatedbyuseofa

time-to-firsteventanalysis.

Twoplacebo-controlledtrials(n=3661)enrolledpostmenopausalwomenunder85yearswithvertebralfractures

atbaseline.Risedronatesodium5mgdailygivenfor3yearsreducedtheriskofnewvertebralfracturesrelative

tothecontrolgroup.Inwomenwithrespectivelyatleast2oratleast1vertebralfractures,therelativerisk

reductionwas49%and41%respectively(incidenceofnewvertebralfractureswithrisedronatesodium18.1%

and11.3%,withplacebo29.0%and16.3%,respectively).Theeffectoftreatmentwasseenasearlyastheend

ofthefirstyearoftreatment.Benefitswerealsodemonstratedinwomenwithmultiplefracturesatbaseline.

Risedronatesodium5mgdailyalsoreducedtheyearlyheightlosscomparedtothecontrolgroup.

Twofurtherplacebocontrolledtrialsenrolledpostmenopausalwomenabove70yearswithorwithoutvertebral

fracturesatbaseline.Women70-79yearswereenrolledwithfemoralneckBMDT-score<-3SD

(manufacturer’srange,i.e.-2.5SDusingNHANESIII)andatleastoneadditionalriskfactor.Women>80

yearscouldbeenrolledonthebasisofatleastonenon-skeletalriskfactorforhipfractureorlowbonemineral

densityatthefemoralneck.Statisticalsignificanceoftheefficacyofrisedronateversusplaceboisonlyreached

whenthetwotreatmentgroups2.5mgand5mgarepooled.Thefollowingresultsareonlybasedona-

posteriorianalysisofsubgroupsdefinedbyclinicalpractiseandcurrentdefinitionsofosteoporosis:

InthesubgroupofpatientswithfemoralneckBMDT-score<-2.5SD(NHANESIII)andatleastonevertebralfracture

atbaseline,risedronatsodiumgivenfor3yearsreducedtheriskofhipfracturesby46%relativetothecontrolgroup

(incidenceofhipfracturesincombinedrisedronatesodium2.5and5mggroups3.8%,placebo7.4%);

Datasuggestthatamorelimitedprotectionthanthismaybeobservedintheveryelderly(>80years).Thismaybedue

totheincreasingimportanceofnon-skeletalfactorsforhipfracturewithincreasingage.

Inthesetrials,dataanalysedasasecondaryendpointindicatedadecreaseintheriskofnewvertebralfracturesin

patientswithlowfemoralneckBMDwithoutvertebralfractureandinpatientswithlowfemoralneckBMDwithor

withoutvertebralfracture.

Risedronatesodium5mgdailygivenfor3yearsincreasedbonemineraldensity(BMD)relativetocontrolatthe

lumbarspine,femoralneck,trochanterandwristandmaintainedbonedensityatthemid-shaftradius.

Inaone-yearfollow-upofftherapyafterthreeyearstreatmentwithrisedronatesodium5mgdailytherewas

rapidreversibilityofthesuppressingeffectofrisedronatesodiumonboneturnoverrate.

Bonebiopsysamplesfrompostmenopausalwomentreatedwithrisedronatesodium5mgdailyfor2to3years,

showedanexpectedmoderatedecreaseinboneturnover.Boneformedduringrisedronatesodiumtreatmentwas

ofnormallamellarstructureandbonemineralisation.Thesedatatogetherwiththedecreasedincidenceof

osteoporosisrelatedfracturesatvertebralsitesinwomenwithosteoporosisappeartoindicatenodetrimental

effectonbonequality.

Endoscopicfindingsfromanumberofpatientswithanumberofmoderatetoseveregastrointestinalcomplaintsinboth

risedronatesodiumandcontrolpatientsindicatednoevidenceoftreatmentrelatedgastric,duodenaloroesophageal

ulcersineithergroup,althoughduodenitiswasuncommonlyobservedintherisedronatesodiumgroup.

TreatmentofOsteoporosisinMen

Risedronatesodium35mgonceaweekdemonstratedefficacyinmenwithosteoporosis(agerange36to84years)ina

2-year,double-blind,placebo-controlledstudyin284patients(risedronatesodium35mgn=191).Allpatientsreceived

supplementalcalciumandvitaminD.

IncreasesinBMDwereobservedasearlyas6monthsfollowinginitiationofrisedronatesodiumtreatment.Risedronate

sodium35mgonceaweekproducedmeanincreasesinBMDatthelumbarspine,femoralneck,trochanterandtotalhip

comparedtoplaceboafter2yearsoftreatment.Antifractureefficacywasnotdemonstratedinthisstudy.

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/05/2012 CRN 2115488 page number: 6

5.2Pharmacokineticproperties

Absorption:Absorptionafteranoraldoseisrelativelyrapid(t

~1hour)andisindependentofdoseovertherange

studied(singledosestudy,2.5to30mg;multipledosestudies,2.5to5mgdailyandupto50mgdosedweekly).Mean

oralbioavailabilityofthetabletis0.63%andisdecreasedwhenrisedronatesodiumisadministeredwithfood.

Bioavailabilitywassimilarinmenandwomen.

Distribution:Themeansteadystatevolumeofdistributionis6.3l/kginhumans.Plasmaproteinbindingisabout24%.

Metabolism:Thereisnoevidenceofsystemicmetabolismofrisedronatesodium.

Elimination:Approximatelyhalfoftheabsorbeddoseisexcretedinurinewithin24hours,and85%ofanintravenous

doseisrecoveredintheurineafter28days.Meanrenalclearanceis105ml/minandmeantotalclearanceis122

ml/min,withthedifferenceprobablyattributedtoclearanceduetoadsorptiontobone.Therenalclearanceisnot

concentrationdependent,andthereisalinearrelationshipbetweenrenalclearanceandcreatinineclearance.

Unabsorbedrisedronatesodiumiseliminatedunchangedinfaeces.Afteroraladministrationtheconcentration-time

profileshowsthreeeliminationphaseswithaterminalhalf-lifeof480hours.

SpecialPopulations

Elderly:nodosageadjustmentisnecessary.

Acetylsalicylicacid/NSAIDusers:AmongregularacetylsalicylicacidorNSAIDusers(3ormoredaysperweek)the

incidenceofuppergastrointestinaladverseeventsinrisedronatesodiumtreatedpatientswassimilartothatincontrol

patients .

5.3Preclinicalsafetydata

Intoxicologicalstudiesinratanddogdosedependentlivertoxiceffectsofrisedronatesodiumwereseen,primarilyas

enzymeincreaseswithhistologicalchangesinrat.Theclinicalrelevanceoftheseobservationsisunknown.Testicular

toxicityoccurredinratanddogatexposuresconsideredinexcessofthehumantherapeuticexposure.Doserelated

incidencesofupperairwayirritationwerefrequentlynotedinrodents.Similareffectshavebeenseenwithother

bisphosphonates.Lowerrespiratorytracteffectswerealsoseeninlongertermstudiesinrodents,althoughtheclinical

significanceofthesefindingsisunclear.Inreproductiontoxicitystudiesatexposuresclosetoclinicalexposure

ossificationchangeswereseeninsternumand/orskulloffoetusesfromtreatedratsandhypocalcemiaandmortalityin

pregnantfemalesallowedtodeliver.Therewasnoevidenceofteratogenesisat3.2mg/kg/dayinratand10mg/kg/dayin

rabbit,althoughdataareonlyavailableonasmallnumberofrabbits.Maternaltoxicitypreventedtestingofhigher

doses.Studiesongenotoxicityandcarcinogenesisdidnotshowanyparticularrisksforhumans.

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

TabletCore:

Lactosemonohydrate

Cellulosemicrocrystalline

CrospovidoneA

Magnesiumstearate

FilmCoating:

Hypromellose

Macrogol

Hyprolose

Silicondioxide

Titaniumdioxide(E171)

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/05/2012 CRN 2115488 page number: 7

Ironoxidered(E172)

6.2Incompatibilities

Notapplicable

6.3Shelflife

Theshelf-lifeexpirydateofthisproductisthedateshownonthecontainerandouterpackageoftheproductonthe

marketinthecountryoforigin.

6.4Specialprecautionsforstorage

Thismedicinalproductdoesnotrequireanyspecialstorageconditions.

6.5Natureandcontentsofcontainer

ClearPVC/aluminiumfoilblistersinanover-labelledcardboardcarton,containing4tablets.

6.6Specialprecautionsfordisposal

Nospecialrequirements

7PARALLELPRODUCTAUTHORISATIONHOLDER

LTTPharmaLimited

Unit18OxleasowRoad

EastMoonMoat

Redditch

WorcestershireB980RE

UnitedKingdom

8PARALLELPRODUCTAUTHORISATIONNUMBER

PPA1562/15/1

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorizations:9thOctober2009

10DATEOFREVISIONOFTHETEXT

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 04/05/2012 CRN 2115488 page number: 8